Findings seen in patients with posterior circulation stroke and with no planned thrombectomy who received alteplase 4.5 to 24 hours after stroke onset.

Download a PDF of the Research Summary. A total of 234 patients were enrolled; 117 were assigned to the alteplase group and 117 to the standard treatment group. The median score on the National ...

Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research ...

The activity and sterility of reconstituted alteplase solution and the effectiveness of an alteplase dose-escalation protocol for the clearance of midlinecatheter and central-venous-access device ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

A new clot-busting drug for stroke works as well as a decades-old drug Patients given tenecteplase had similar outcomes to those given alteplase Tenecteplase is easier to administer, giving doctors ...

Recombinant human prourokinase is noninferior to alteplase in acute ischemic stroke, with symptomatic intracranial hemorrhage and major bleeding decreased.

Extending the treatment window for intravenous thrombolysis beyond 4.5 hours may benefit patients with posterior circulation ischemic stroke. New research findings are summarized in a short video.

For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes.

Alteplase administered 4.5 to 24 hours after mild posterior circulation ischemic stroke onset increases the likelihood of functional independence at 90 days compared to standard care.

And now, research shows that tenecteplase works just as well as the standard clot-busting drug alteplase used to treat strokes, according to findings published recently in JAMA Network Open.